Business Context and Reporting Period
This Form 8-K is filed by Aikido Pharma Inc. (not Dominari Holdings Inc.) on June 28, 2022. The report addresses a specific regulatory event regarding the company's listing status on The Nasdaq Stock Market.
Key Financial Metrics
This filing is a Current Report (Item 8.01) and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
- Nasdaq Compliance Regained: The Company previously received a deficiency notice on August 10, 2021, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days.
- Resolution: On June 23, 2022, Nasdaq notified the Company that it had regained compliance with Listing Rule 5550(a)(2). This was achieved because the closing bid price was at or above $1.00 per share for the 11 consecutive business days from June 7 through June 22, 2022.
- Status: Nasdaq has officially considered this matter closed.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on operations, or new risk factors. The primary focus is the resolution of the prior listing deficiency. A press release dated June 28, 2022, announcing this compliance is filed as Exhibit 99.1.
Investor Verification Checklist
- Verify the current trading price of Aikido Pharma Inc. (Ticker: AIKI) to ensure it remains above the $1.00 threshold to avoid future deficiency notices.
- Review the press release filed as Exhibit 99.1 for any additional context on the stock price performance during the compliance period.
- Confirm that no other pending regulatory actions exist with Nasdaq or the SEC.